Is Patience Really A Virtue For Investors In Aviva plc, GlaxoSmithKline plc And Unilever plc?

Aviva plc (LON: AV), GlaxoSmithKline plc (LON: GSK) and Unilever plc (LON: ULVR) have disappointed lately and Harvey Jones examines whether investors should stay faithful to them

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Patience is one of the most underestimated virtues among investors. Too many dive in hoping to make a quick buck, failing to realise that the true rewards of investing in stocks and shares lie in the longer run.

Buying strong, established globally exposed businesses with excellent share price growth and dividend progression won’t make you rich overnight, but should make you far wealthier in the longer run. Many investors will be holding Aviva (LSE: AV), GlaxoSmithKline (LSE: GSK) and Unilever (LSE: ULVR) for exactly these reasons, but — given recent setbacks — has their patience been stretched too far?

Aviva Fever

Insurance giant Aviva has been embarrassed by insurance rivals Legal & General and Prudential over the last five years. It returned a mere 13% in that time, against a spectacular 145% for L&G and 125% from the Pru.

Many investors, including me, bought Aviva because they hoped it would play a lucrative game of catch-up. We swallowed our disappointment when it slashed its dividend by a quarter in March 2013 to fund its turnaround strategy and hung on, waiting for management to build a leaner, meaner business.

Half-year results show Aviva is still a work in progress. The share price turnaround is taking longer than we all hoped. Its relatively high exposure to Europe has held it back, even if its prime UK market has done better. Aviva’s lack of Asia exposure looks less of a disadvantage given troubled emerging markets. At today’s valuation of less than 10 times earnings, it is clear that some investors have lost patience. The dividend is being rebuilt but at today’s 3.86% yield, investors’ patience may be better rewarded elsewhere. I’m giving it one more go, though.

Glaxo Fails To Go

For years, GlaxoSmithKline seemed the simplest and security way of making a long-term killing on the stock markets: buy its shares, reinvest the juicy dividends for growth, and let time do the rest.

Then things started to go wrong, starting with the Chinese bribery scandal, followed by patent expiries and late-stage failures and falling sales. Glaxo is now trading at the same price it was five years ago. Over the last six months, it is down 20%, which smarts. It is no longer a safe harbour in stock market storms.

New buyers may be tempted by its relatively lowly valuation of 13.52 times earnings. Loyal investors can comfort themselves with the whacking yield, now 6.18%, and pray it doesn’t get cut. There is hope, as Glaxo restructures and integrates Novartis, new products promise £6bn of annual sales by 2020, and management stands by the dividend. Glaxo should still reward those who bide their time.

Unilever Moves The World

Household goods giant Unilever is another classic FTSE 100 buy-and-hold stock. It was always expensive as a result, typically trading at 20 times earnings or more, and yielding little more than 2%. After a year of underperformance those numbers have changed dramatically. Finally, investors can buy it at a modestly priced 15.8 times earnings and pocket an almost decent 3.46% yield.

Sales, earnings and margins were still up in the first half, despite headwinds in China and emerging markets. Chief executive Paul Polman’s pledge to deliver “consistent, competitive, profitable and responsible growth” looks eminently achievable, given its unbeatable portfolio of everyday branded products. Like Glaxo, Unilever now appears to offer a rare buying opportunity. But only if you’re prepared to be patient. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones holds shares in Aviva. The Motley Fool UK owns and has recommended Unilever. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »